3SBio Inc.
1530
株式のランク
#3616
Operating as an investment holding company, 3SBio Inc. specializes in the full... Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
株価
$1.86
時価総額
$4.66B
変化（1日）
0.62%
変化（1年）
-48.51%
国
CN
取引 3SBio Inc. (1530)
カテゴリー
Healthcare
3SBio Inc.（1530）の営業利益率
October 2026 時点の営業利益率 TTM: 61.16%
3SBio Inc. の最新の財務報告と株価によると、現在の営業利益率（TTM）は 61.16% です。2023 年末時点では 31.45% でした。
3SBio Inc. の営業利益率の履歴（2012 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | 61.16% | 110.32% |
| 2024 | 29.08% | -7.54% |
| 2023 | 31.45% | 4.24% |
| 2022 | 30.17% | 5.42% |
| 2021 | 28.62% | 9.40% |
| 2020 | 26.16% | 4.14% |
| 2019 | 25.12% | -20.25% |
| 2018 | 31.50% | 1.81% |
| 2017 | 30.94% | -4.77% |
| 2016 | 32.49% | 13.56% |
| 2015 | 28.61% | -14.80% |
| 2014 | 33.58% | 5.46% |
| 2013 | 31.84% | 57.08% |
| 2012 | 20.27% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 38.59% | -99.37% |
US
|
|
| -149.01% | -102.44% |
US
|
|
| 25.57% | -99.58% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.53% |
NL
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。